城市配音

　　 企业宣传片

　　In the past 9 years, driven by our mission to develop, manufacture and commercialize

　　high quality, innovative and affordable vaccines, CanSinoBIO takes every significant

　　step to carry that goal forward.

　　Fulfilling this mission is our exceptional founders and senior management team – a

　　deep bench of world-class scientists with a record of leading the development of

　　international blockbuster vaccines at global pharmaceutical companies such as Sanofi

　　Pasteur, AstraZeneca, Pfizer and Novartis.

　　China vaccine market is vast and underserved. The sales revenue of vaccine per

　　person in China was only 2.9US$ in 2017, which was less than 6% of the U.S., but is

　　expected to grow more rapidly as driven by the expansion of the private vaccine

　　market. （The customer has modified and needs to re-record the red font）

　　CanSinoBIO has a comprehensive and robust product pipeline.

　　We have two near-commercial assets with high potential. Our MCV4 candidate is a

　　potential China first-in-class vaccine preventing meningitis.

　　Our MCV2 candidate is a potential China best-in-class bi-valent meningococcal

　　vaccine with a better safety profile and a better immunogenicity.

　　Our Ad5-EBOV is the first approved Ebola virus vaccine in China for emergency use

　　and national stockpile. It has better stability profile and does not require ultra-low

　　storage temperature conditions, as compared to competing products from

　　multi-national companies. （[virus] is not recorded in audio）

　　Our DTcP Infant candidate and DTcP Booster candidate are, respectively,

　　potential China’s best-in-class DTcP vaccine for infants and potential China’s

　　first-in-class DTcP booster vaccine for children, which with fixed and consistent

　　composition of each antigen, significantly better and consistent immunogenicity and

　　less safety concern than currently marketed co-purified DTaP vaccines. Our Tdcp

　　Adolescent and Adult candidate is potential global best-in-class Tdcp vaccines for

　　Adolescents and Adults.

　　At the same time, we are developing two potential blockbuster vaccines preventing

　　pneumococcal diseases, namely PBPV and PCV13i（读：PCV thirteen i).. Our

　　PBPV is a globally innovative，Serotype-independent protein-based pneumococcal

　　vaccine candidate which has received CTA approval, and primarily protect against

　　community acquired pneumococcal diseases among the elderly. Our PCV13i

　　(Improved 13 valent Pneumococcal Conjugate Vaccine) is a potential best

　　pneumococcal conjugate vaccine which has shown better immunogenicity than

　　Prevnar 13.

　　CanSinoBIO has developing a globally innovative TB booster vaccine candidate for

　　BCG-vaccinated population. The phase Ia（one A） clinical trial showed this

　　vaccine candidate to be safe, well tolerated and able to boost the immunogenicity.

　　We are conducting the Phase Ib（one b） clinical trial in Canada.

　　In addition, we have six pre-clinical vaccine candidates.

　　(This is the beginning of a new paragraph. The overall style needs to have

　　feelings and the pitch can be higher.[will] need to pay attention to the

　　pronunciation.)

　　CanSinoBIO has global-standard vaccine manufacturing capabilities and quality

　　control system.

　　We own and operate a manufacturing facility with international standards. We believe

　　the annual bulk production capacity will fully support our commercialization plans for

　　our near-commercial candidates as well as supporting phase III trial materials in the

　　foreseeable future.

　　We have four advanced platform technologies.

　　(The following are the companys expectations for the future. The overall feeling

　　needs to be passionate.[will] need to pay attention to the pronunciation.)

　　Going forward, CanSinoBIO will：

　　Advance the development and commercialization of near-commercial assets including

　　our two MCV candidates and Ad5-EBOV, and our pipeline of other vaccine

　　candidates.

　　Establish and strengthen our commercialization infrastructure.

　　Through global collaborations and acquisition opportunities, we will be a partner of

　　choice for global vaccine companies seeking to unlock the value of their assets in the

　　China market.

　　CanSino Biologics Inc.:

　　Together, we build a world full of health, hope and promise.

经典纪录片配音经典纪录片配音经典纪录片配音